GV20 Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, GV20 Therapeutics sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).
GV20 Therapeutics: 1 sponsored US clinical trial, 1 recruiting.
GV20 Therapeutics sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is pMMR/MSS Adenocarcinoma of the Colon or Rectum, with 1 trials.
Mid-pack sponsor footprint
GV20 Therapeutics is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
What is open in the GV20 Therapeutics pipeline
1 recruiting of 1 indexed (100% open).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: pMMR/MSS Adenocarcinoma of the Colon or Rectum (1 trial), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
GV20 Therapeutics: open-pipeline peers nationwide
Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
GV20 Therapeutics sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this GV20 Therapeutics page
1 registered trials is a research-attention snapshot, not an endorsement of GV20 Therapeutics or any single study.
- 1 of GV20 Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- pMMR/MSS Adenocarcinoma of the Colon or Rectum is the condition GV20 Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See pMMR/MSS Adenocarcinoma of the Colon or Rectum trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. GV20 Therapeutics pipeline card: 1 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.